Patents by Inventor Bjarne Bogen
Bjarne Bogen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12268736Abstract: Provided herein is technology relating to vaccines and particularly, but not exclusively, to compositions, methods, and uses of heterodimer vaccine molecules formed from monomers comprising a targeting unit and a variant antigenic unit joined by heterodimerization units.Type: GrantFiled: September 7, 2018Date of Patent: April 8, 2025Assignee: University of OsloInventors: Ranveig Braathen, Bjarne Bogen
-
Publication number: 20240325519Abstract: Provided herein is technology relating to vaccines and particularly, but not exclusively, to compositions, methods, and uses of a mixture of immunogenic vaccine molecules comprising components for targeting the dimeric vaccine molecules to antigen-presenting cells and components for eliciting an immunogenic response, wherein the components for eliciting an immunogenic response preferably comprise at least three variants of an immunogenic protein, such as variants of immunogenic proteins obtained from three or more different strains of a pathogenic organism.Type: ApplicationFiled: June 10, 2024Publication date: October 3, 2024Inventors: Gunnveig Grødeland, Bjarne Bogen, Ane Marie Anderson
-
Publication number: 20240228624Abstract: The present invention relates to an immunoglobulin derived single-chain fragment variable (scFv) that broadly binds HLA II molecules and uses thereof. In particular, targeting of an antigen to antigen presenting cells with the HLAII-specific targeting unit provided herein find use in enhancing immune responses after vaccination.Type: ApplicationFiled: September 19, 2023Publication date: July 11, 2024Inventors: Gunnveig Grodeland, Bjarne Bogen, Agnete B. Fredriksen
-
Patent number: 12005112Abstract: Provided herein is technology relating to vaccines and particularly, but not exclusively, to compositions, methods, and uses of a mixture of immunogenic vaccine molecules comprising components for targeting the dimeric vaccine molecules to antigen-presenting cells and components for eliciting an immunogenic response, wherein the components for eliciting an immunogenic response preferably comprise at least three variants of an immunogenic protein, such as variants of immunogenic proteins obtained from three or more different strains of a pathogenic organism.Type: GrantFiled: September 7, 2018Date of Patent: June 11, 2024Assignee: University of OsloInventors: Gunnveig Grødeland, Bjarne Bogen, Ane Marie Anderson
-
Publication number: 20240132596Abstract: The present invention relates to an immunoglobulin derived single-chain fragment variable (scFv) that broadly binds HLA II molecules and uses thereof. In particular, targeting of an antigen to antigen presenting cells with the HLAII-specific targeting unit provided herein find use in enhancing immune responses after vaccination.Type: ApplicationFiled: September 18, 2023Publication date: April 25, 2024Inventors: Gunnveig Grodeland, Bjarne Bogen, Agnete B. Fredriksen
-
Patent number: 11780924Abstract: The present invention relates to an immunoglobulin derived single-chain fragment variable (scFv) that broadly binds HLA II molecules and uses thereof. In particular, targeting of an antigen to antigen presenting cells with the HLAII-specific targeting unit provided herein find use in enhancing immune responses after vaccination.Type: GrantFiled: June 21, 2017Date of Patent: October 10, 2023Assignees: UNIVERSITY OF OSLO, NYKODE THERAPEUTICS ASAInventors: Gunnveig Grodeland, Bjarne Bogen, Agnete B. Fredriksen
-
Publication number: 20230303718Abstract: Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.Type: ApplicationFiled: February 2, 2023Publication date: September 28, 2023Applicant: NYKODE THERAPEUTICS ASAInventors: Bjarne BOGEN, Agnete Brunsvik FREDRIKSEN, Inger SANDLIE
-
Publication number: 20230065226Abstract: The present invention relates to novel recombinant fusion proteins, such as human antibody-based molecules called Vaccibodies, which are able to trigger both a T cell- and B cell immune response. The present invention also relates to a method of treating a cancer or an infectious disease by means of these specific fusion proteins.Type: ApplicationFiled: September 22, 2022Publication date: March 2, 2023Applicant: Nykode Therapeutics ASAInventors: Pier Adelchi Ruffini, Bjarne Bogen, Agnete Brunsvik Fredriksen
-
Publication number: 20230048561Abstract: Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.Type: ApplicationFiled: March 8, 2022Publication date: February 16, 2023Applicant: NYKODE THERAPEUTICS ASAInventors: Bjarne BOGEN, Agnete B. FREDRICKSEN, Inger SANDLIE
-
Patent number: 11479605Abstract: The present invention relates to novel recombinant fusion proteins, such as human antibody-based molecules called Vaccibodies, which are able to trigger both a T cell- and B cell immune response. The present invention also relates to a method of treating a cancer or an infectious disease by means of these specific fusion proteins.Type: GrantFiled: February 7, 2020Date of Patent: October 25, 2022Assignee: Nykode Therapeutics ASAInventors: Pier Adelchi Ruffini, Bjarne Bogen, Agnete Brunsvik Fredriksen
-
Publication number: 20220118076Abstract: Provided herein is technology relating to vaccines and particularly, but not exclusively, to compositions, methods, and uses of heterodimer vaccine molecules formed from monomers comprising a targeting unit and a variant antigenic unit joined by heterodimerization units.Type: ApplicationFiled: September 7, 2018Publication date: April 21, 2022Inventors: Ranveig Braathen, Bjarne Bogen
-
Publication number: 20210403572Abstract: The present invention relates to an immunoglobulin derived single-chain fragment variable (scFv) that broadly binds HLA II molecules and uses thereof. In particular, targeting of an antigen to antigen presenting cells with the HLAII-specific targeting unit provided herein find use in enhancing immune responses after vaccination.Type: ApplicationFiled: June 21, 2017Publication date: December 30, 2021Inventors: Gunnveig Grodeland, Bjarne Bogen, Agnete B. Fredriksen
-
Publication number: 20210069319Abstract: Provided herein is technology relating to vaccines and particularly, but not exclusively, to compositions, methods, and uses of a mixture of immunogenic vaccine molecules comprising components for targeting the dimeric vaccine molecules to antigen-presenting cells and components for eliciting an immunogenic response, wherein the components for eliciting an immunogenic response preferably comprise at least three variants of an immunogenic protein, such as variants of immunogenic proteins obtained from three or more different strains of a pathogenic organism.Type: ApplicationFiled: September 7, 2018Publication date: March 11, 2021Inventors: Gunnveig Grødeland, Bjarne Bogen, Ane Marie Anderson
-
Publication number: 20200239568Abstract: The present invention relates to novel recombinant fusion proteins, such as human antibody-based molecules called Vaccibodies, which are able to trigger both a T cell- and B cell immune response. The present invention also relates to a method of treating a cancer or an infectious disease by means of these specific fusion proteins.Type: ApplicationFiled: February 7, 2020Publication date: July 30, 2020Applicant: Vaccibody ASInventors: Pier Adelchi Ruffini, Bjarne Bogen, Agnete Brunsvik Fredriksen
-
Patent number: 10590195Abstract: The present disclosure relates to recombinant fusion proteins, such as human antibody-based molecules called Vaccibodies, which are able to trigger both a T cell- and B cell immune response. The present disclosure also relates to a method of treating a cancer or an infectious disease by means of these specific fusion proteins.Type: GrantFiled: June 24, 2011Date of Patent: March 17, 2020Assignee: VACCIBODY ASInventors: Pier Adelchi Ruffini, Bjarne Bogen, Agnete Brunsvik Fredriksen
-
Publication number: 20180030155Abstract: Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.Type: ApplicationFiled: October 12, 2017Publication date: February 1, 2018Applicant: Vaccibody ASInventors: Bjarne BOGEN, Agnete Brunsvik FREDRIKSEN, Inger SANDLIE
-
Patent number: 9802999Abstract: The present invention relates to a fusion protein comprising a first peptide and a second peptide linked together with a linker, wherein the first peptide is an allergen and the second peptide is a targeting unit and the targeting unit is a FGL-2 C-terminal peptide according to SEQ ID no 1. Provided herein are also uses of said fusion protein as a vaccine for treating allergy, such as shrimp, peanut or mite allergy, as well as a vaccine composition and methods for producing such fusion proteins.Type: GrantFiled: October 30, 2013Date of Patent: October 31, 2017Assignee: VETERINAERINSTITUTTETInventors: Maaike Maria Barbara Wilhelmina Dooper, Bjarne Bogen, Heidi Ragnhild Myrset
-
Patent number: 9796787Abstract: Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.Type: GrantFiled: October 1, 2015Date of Patent: October 24, 2017Assignee: Vaccibody A/SInventors: Bjarne Bogen, Agnete Brunsvik Fredriksen, Inger Sandlie
-
Publication number: 20160039946Abstract: Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.Type: ApplicationFiled: October 1, 2015Publication date: February 11, 2016Inventors: Bjarne BOGEN, Agnete Brunsvik FREDRIKSEN, Inger SANDLIE
-
Patent number: 9169322Abstract: Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.Type: GrantFiled: January 19, 2012Date of Patent: October 27, 2015Assignee: Vaccibody ASInventors: Bjarne Bogen, Agnete Brunsvik Fredriksen, Inger Sandlie